<code id='318F0E964F'></code><style id='318F0E964F'></style>
    • <acronym id='318F0E964F'></acronym>
      <center id='318F0E964F'><center id='318F0E964F'><tfoot id='318F0E964F'></tfoot></center><abbr id='318F0E964F'><dir id='318F0E964F'><tfoot id='318F0E964F'></tfoot><noframes id='318F0E964F'>

    • <optgroup id='318F0E964F'><strike id='318F0E964F'><sup id='318F0E964F'></sup></strike><code id='318F0E964F'></code></optgroup>
        1. <b id='318F0E964F'><label id='318F0E964F'><select id='318F0E964F'><dt id='318F0E964F'><span id='318F0E964F'></span></dt></select></label></b><u id='318F0E964F'></u>
          <i id='318F0E964F'><strike id='318F0E964F'><tt id='318F0E964F'><pre id='318F0E964F'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:entertainment    Page View:476

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In